Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 33 molecules. Out of which approximately 33 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 2, 1, 1, 8, 5 and 1 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Metastatic Colorectal Cancer, Non-Proliferative Diabetic Retinopathy (NPDR), Retinal Vein Occlusion, Retinopathy, Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Choroidal Neovascularization, Colorectal Cancer, Corneal Neovascularization, Graves' Ophthalmopathy, Macular Degeneration, Medulloblastoma, Optic Neuropathy, Retinoblastoma, Retinopathy Of Prematurity, Solid Tumor, Unspecified Cancer, Unspecified Ophthalmological Disorders and Uveal Melanoma.
The latest report Placenta Growth Factor - Drugs In Development, 2022, outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
• The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects
• The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope